Moderna
Trade Moderna 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics.
MRNA Key Statistics
Stock Snapshot
Moderna(MRNA) stock is priced at $59.40, giving the company a market capitalization of 23.61B. It carries a P/E multiple of -7.41.
During the trading session on 2026-08-08, Moderna(MRNA) shares reached a daily high of $59.44 and a low of $54.51. At a current price of $59.40, the stock is +9.0% higher than the low and still -0.1% under the high.
Trading volume for Moderna(MRNA) stock has reached 6.82M, versus its average volume of 5.4M.
Over the past 52 weeks, Moderna(MRNA) stock has traded between a high of $85.60 and a low of $22.28.
Over the past 52 weeks, Moderna(MRNA) stock has traded between a high of $85.60 and a low of $22.28.
MRNA News
The Food and Drug Administration has approved Moderna (MRNA) mFlusiva vaccine for adults aged 50 and over, marking the first U.S. influenza shot to use mRNA tec...
This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herei...
Moderna stock (MRNA) fell 1.5% to $55.39 on Thursday despite getting big news from health regulators. The Food and Drug Administration approved Moderna’s new fl...
Analyst ratings
65%
of 26 ratingsMore MRNA News
Technology Moderna Wavers Despite Hard-Fought FDA Win; Will Its Sprint Restart? Licensing Moderna (MRNA) stock wavered Thursday after the Food and Drug Administ...
Moderna (MRNA) announced that the FDA has approved mFlusiva, a new vaccine against seasonal influenza, for use in all adults 50 years and older. This approval f...
Moderna (NasdaqGS:MRNA) has started the first Phase 1 clinical trial of an mRNA vaccine targeting the Bundibugyo strain of the Ebola virus. The trial follows a...
Moderna (MRNA) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident inves...
Moderna Begins Phase 1 Trial For Ebola Vaccine Moderna has initiated a Phase 1 clinical trial evaluating mRNA-1469, an investigational vaccine designed to prev...
Key Points Axsome Therapeutics' new launches and label expansions should improve its financial results. Moderna is close to a brand-new approval that would he...
Biotech and Pharma Moderna Stock Jumps on Trial Launch for Breakthrough Ebola Vaccine In this article MRNA MRK IDNA SPX Moderna is developing a vaccine candidat...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.